Stift Carlanderska Sjukhuset

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Type 2 diabetes4 trials
• Obesity3 trials
• Coronary artery disease1 trial
• Graves' disease and hyperthyroidism1 trial
• Heart failure1 trial
• High blood pressure1 trial
• Stroke1 trial

Phase

• Phase 36 trials
• Phase 41 trial

Status

• Completed4 trials
• Recruiting2 trials
• Not yet recruiting1 trial

Lead sponsor

• Boehringer Ingelheim3 trials
• Amgen1 trial
• Amgen Inc.1 trial
• argenx1 trial
• Uppsala University1 trial

Running trials

• Recruiting

  A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.

  NCT07596849· Phase 3· argenx· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

  2024-516654-22-00· Phase 3· Amgen Inc.· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Graves' disease and hyperthyroidism1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• Obesity1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

  NCT06066528· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

  NCT06066515· Phase 3· Boehringer Ingelheim· Source

• Completed

  SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes

  NCT03982381· Phase 4· Uppsala University· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Amgen· Source